{"id":806293,"date":"2026-07-17T14:58:08","date_gmt":"2026-07-17T14:58:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/806293\/"},"modified":"2026-07-17T14:58:08","modified_gmt":"2026-07-17T14:58:08","slug":"2-5m-department-of-defense-grant-funds-triple-negative-breast-cancer-therapies","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/806293\/","title":{"rendered":"$2.5M Department of Defense grant funds triple-negative breast cancer therapies"},"content":{"rendered":"<p>Weill Cornell Medicine has received a three-year, $2.5 million grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers.<\/p>\n<p>The highly competitive DoD Breast Cancer Research Program Breakthrough Award supports innovative projects with strong potential to transform breast cancer treatment.<\/p>\n<p>Triple-negative breast cancer lacks three proteins \u2013 estrogen receptor, progesterone receptor and HER2 \u2013 that many of today\u2019s targeted therapies attack, leaving many patients limited to chemotherapy as their primary treatment option.\u00a0<\/p>\n<p>\u201cPatients with triple-negative breast cancer urgently need better treatment options,\u201d said co-principal investigator\u00a0<a href=\"https:\/\/vivo.weill.cornell.edu\/display\/cwid-xim2002\" rel=\"nofollow noopener\" target=\"_blank\">Xiaojing Ma<\/a>, professor of microbiology and immunology and a member of the\u00a0<a href=\"https:\/\/meyercancer.weill.cornell.edu\/\" rel=\"nofollow noopener\" target=\"_blank\">Sandra and Edward Meyer Cancer Center<\/a> at Weill Cornell.\u00a0<\/p>\n<p>Ma is working with\u00a0<a href=\"https:\/\/vivo.weill.cornell.edu\/display\/cwid-gal2005\" rel=\"nofollow noopener\" target=\"_blank\">Gang Lin<\/a>, professor of research in microbiology and immunology at Weill Cornell and co-principal investigator, to develop first-in-class drugs targeting UBR5, a protein that is frequently overproduced in aggressive breast cancers and several other difficult-to-treat malignancies. Unlike most existing therapies, targeting UBR5 has the potential to simultaneously interfere with multiple cancer-promoting mechanisms.<\/p>\n<p>\u201cWe believe the UBR5 protein is an entirely new vulnerability in these tumors,\u201d Ma said, \u201cand this award provides an opportunity to translate years of basic discovery into therapies that could ultimately benefit patients.\u201d<\/p>\n<p>In healthy cells, UBR5 helps regulate the activity and turnover of many proteins involved in cell growth, DNA repair and tagging damaged or faulty proteins for disposal. However, Ma and his team previously discovered that many cancers hijack UBR5 to promote tumor growth, spread and resistance to immune attack.<\/p>\n<p>In a highly cited 2017\u00a0<a href=\"https:\/\/aacrjournals.org\/cancerres\/article\/77\/8\/2090\/625020\/E3-Ubiquitin-Ligase-UBR5-Drives-the-Growth-and\" rel=\"nofollow noopener\" target=\"_blank\">paper<\/a>, Ma\u2019s lab showed that genetically disrupting the UBR5 gene in preclinical models slowed breast tumor growth and reduced the ability of cancer cells to metastasize to other organs. The findings provided the first compelling evidence that UBR5 is not merely associated with breast cancer but is functionally required for tumor growth and metastasis, motivating the team\u2019s effort to develop drugs that target the protein.<\/p>\n<p>Ma partnered with Lin, a medicinal chemist well-versed in developing drugs that interfere with the actions of specific proteins. In addition to designing small molecule drugs that block UBR5, the researchers will develop protein degraders, an emerging type of medicine that directs the cell\u2019s own waste-disposal system to destroy harmful proteins. Because many tumors produce substantially higher levels of UBR5 than most normal tissues, the researchers anticipate these therapies will selectively target cancer cells while reducing side effects.<\/p>\n<p>Together, their labs have already uncovered several compounds that inhibit UBR5 at high concentrations, providing the proof-of-concept needed to launch the current project.<\/p>\n<p>\u201cThe potency is not ideal yet; achieving an effective dose on-target requires high concentrations that may induce side effects,\u201d Lin said. \u201cThis grant will help us tweak the structures of the inhibitors to make them effective at much lower concentrations.\u201d<\/p>\n<p>The team will then evaluate how well the drugs work against breast cancer in laboratory models that closely mimic human cancers. \u201cA big win will be optimizing these drug candidates and generating the data needed to move into the next phase of development,\u201d Lin said.\u00a0<\/p>\n<p>\u201cAlthough the current project focuses on triple-negative breast cancer, UBR5 is also overproduced in ovarian, pancreatic and prostate cancers,\u201d Ma said. \u201cSuccess in this program could open the door to a new generation of targeted therapies for multiple aggressive cancers.\u201d<\/p>\n<p>Saima Sidik is a freelance writer for Weill Cornell Medicine.<\/p>\n","protected":false},"excerpt":{"rendered":"Weill Cornell Medicine has received a three-year, $2.5 million grant from the Department of Defense (DoD) to develop&hellip;\n","protected":false},"author":2,"featured_media":806294,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[64,63,137],"class_list":["post-806293","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-au","tag-australia","tag-health"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/806293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=806293"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/806293\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/806294"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=806293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=806293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=806293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}